NewsRoom Articles - Page 55 of 154 - PsychedelicNewsWire (PNW)

FridayJul 01, 2022 11:11 am

Study Finds That DMT May Be Used to Effectively Treat Depression

Anyone who has used DMT (N, N-dimethyltryptamine) knows that it is a powerful hallucinogen that can induce immersive hallucinations in only a few minutes. The drug’s effects are similar to those of other psychedelics, including psilocybin mushrooms and LSD. Now that psychedelics are seeing a resurgence in popularity, researchers have been interested in how these drugs can impact mental health. According to a new study published in the “Nature” journal, DMT may have the potential to treat depression. The researchers’ objective was to see whether administering DMT would have any effect on patients with depressive symptoms. Researchers discovered that patients…

ThursdayJun 30, 2022 2:00 pm

Appeal Board Upholds Compass Pathways’ Patent on Synthetic Psilocybin Formulation

A psychedelics company recently scored a major win after the Patent Trial and Appeal Board (PTAB) upheld a novel psychedelic patent that was under challenge. Compass Pathways PLC (NASDAQ: CMPS), a mental healthcare company based in the United Kingdom, synthesized and patented a type of psilocybin called Comp 360. In late 2021, a nonprofit called Freedom to Operate issued a legal challenge against the patents, arguing that Comp 360, which is also known as Polymorph A, was not a new and unique invention. The nonprofit stated that the synthetic psilocybin existed in the public domain and was not a novel…

WednesdayJun 29, 2022 1:10 pm

NJ Senate President Introduces Psilocybin Legalization Bill Containing Home-Cultivation Provision

New Jersey’s senate president recently filed a bill that would legalize the home cultivation, possession and gifting of psilocybin or magic mushrooms to adults aged 21 and older. The psychedelic reform bill contains provisions that would grant the psychedelics market more freedoms than the cannabis market. Last February, New Jersey Governor Phil Murphy signed a bill that reclassified the possession of psilocybin mushrooms from a third-degree crime with a penalty of three to five years in jail and up to $15,000 in fines to a disorderly persons offense with a maximum fine of $1,000, up to six months’ jail time,…

TuesdayJun 28, 2022 1:55 pm

Psychedelics Voter Initiatives That May Qualify for Ballot in Colorado

Colorado residents may soon be able to vote on the decriminalization and regulation of psychedelics. If two voter initiatives centered around psychedelics qualify for the ballot, voters in Colorado could vote to decriminalize psychedelics during the November ballot. Initiative 58 and initiative 61 are currently in the signature-gathering stage, with each having to collect no less than 124,635 valid signatures by Aug. 8, 2022, to qualify for the ballot. Initiative 61, Legal Possession and Use of Entheogenic Plants and Fungi, would decriminalize the personal possession and use of specific entheogenic fungi and plants for adults aged 21 years and older.…

MondayJun 27, 2022 2:48 pm

What Investors Interested in Psychedelics Need to Focus on Regarding IP Issues

The psychedelics market is expected to record significant growth over the next decade as researchers uncover more ways psychedelics can be used to treat mental health conditions. With industry projections showing that psychedelics may even surpass the extremely lucrative cannabis industry, one question that remains in some stakeholders’ minds is how the psychedelic market will deal with IP issues as it grows. Psychedelics present a curious situation that makes a variety of the substances ineligible for patent protection. For example, while pharmaceutical companies that develop and synthesize chemical compounds in the lab are allowed to patent their drugs, psychedelics such…

MondayJun 27, 2022 2:15 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Reports Initial Results from Feasibility Study

Study indicates that ketamine-induced changes in functional connectivity last for several days after administration of the substance Kernel Flow gathers real-time functional brain activity during clinical and research studies evaluating psychedelic-based therapeutics Technology is “precisely what we need to accelerate the development of psychedelics into therapeutics,” says Cybin CEO New data confirms Cybin’s (NEO: CYBN) (NYSE American: CYBN) focus on and commitment to progressing psychedelics to therapeutics. The company’s feasibility study using Kernel Flow confirms the device’s ability to successfully measure the neuro-effect of ketamine (https://ibn.fm/blLwT), based on study results presented at the PSYCH Symposium in London. Cybin has announced that…

MondayJun 27, 2022 1:30 am

Silo Pharma Inc. (SILO) Takes Aim at Alzheimer’s Disease

In October 2021, Silo Pharma (OTCQB: SILO) entered into a sponsored research agreement (“SRA”) with Columbia University to investigate and advance psychedelic therapeutics for Alzheimer's Disease (“AD”). SRA’s grant Silo access to world-class research facilities to sponsor potential life-changing research while offering Silo licensing opportunities for groundbreaking psychedelic remedies. Columbia University Irving Medical Center (“CUIMC”), an “internationally recognized leader” in research and therapeutic development, partnered with Silo to study psychedelics’ ability to improve, slow, or even reverse functional decline and memory loss associated with Alzheimer's disease. Associate Professor of Clinical Neurobiology, Dr. Christine Ann Denny, helming the research for Silo,…

FridayJun 24, 2022 2:48 pm

New Netflix Series to Explore the Use of Psychedelics for Mental Health

Over the last decade or so, a growing body of research has revealed a link between mental health and psychedelics. Researchers have found that psychedelic drugs such as LSD and psilocybin have the potential to alleviate mental health conditions, including depression and post-traumatic stress disorder (PTDS). Now a new documentary from Netflix seeks to teach viewers about some of the mental health outcomes associated with psychedelic use. The documentary is named after Michael Pollan’s book, titled “How to Change Your Mind,” which was originally published in 2018. It will be adapted into film by Academy Award-Winning documentary film director and…

ThursdayJun 23, 2022 10:41 am

Four Psychedelics ETF Investors Are Interested In

Renewed interest in psychedelics in both public and scientific spaces has increased investor interest in psychedelic stocks. The psychedelic market is projected to achieve a valuation of $10.7 billion by 2027, and investors are looking to cash in on the industry before it is saturated. However, the industry is still in its infancy and presents a high degree of risk. As such, psychedelic ETFs or exchange-traded funds that allow investors to buy a bundle of several stocks rather than one have been the focal point of investor interest as they allow diversified risk. Below are a couple of ETFs investors…

WednesdayJun 22, 2022 3:47 pm

Study Finds Frequent Nightmares May Be Sign of Parkinson’s Disease Development

Are you an older man who has been experiencing regular nightmares as you age? A new study suggests that this may be an early warning sign of Parkinson’s disease. Parkinson’s is a brain disorder that causes uncontrollable movements and makes it increasingly difficult for patients to talk and walk in its advanced stages. With at least one-quarter of patients suffering from Parkinson’s reporting that they experience upsetting dreams regularly, scientists have spent the last few years investigating the link between Parkinson’s and sleep. This new study, which is the first of its kind, was designed to investigate whether developing nightmares…

News and publishing service for psychedelic related companies

Contact us: 512.354.7000